TITLE

The script concordance test in radiation oncology: validation study of a new tool to assess clinical reasoning

AUTHOR(S)
Lambert, Carole; Gagnon, Robert; Nguyen, David; Charlin, Bernard
PUB. DATE
January 2009
SOURCE
Radiation Oncology;2009, Vol. 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The Script Concordance test (SCT) is a reliable and valid tool to evaluate clinical reasoning in complex situations where experts' opinions may be divided. Scores reflect the degree of concordance between the performance of examinees and that of a reference panel of experienced physicians. The purpose of this study is to demonstrate SCT's usefulness in radiation oncology. Methods: A 90 items radiation oncology SCT was administered to 155 participants. Three levels of experience were tested: medical students (n = 70), radiation oncology residents (n = 38) and radiation oncologists (n = 47). Statistical tests were performed to assess reliability and to document validity. Results: After item optimization, the test comprised 30 cases and 70 questions. Cronbach alpha was 0.90. Mean scores were 51.62 (± 8.19) for students, 71.20 (± 9.45) for residents and 76.67 (± 6.14) for radiation oncologists. The difference between the three groups was statistically significant when compared by the Kruskall-Wallis test (p < 0.001). Conclusion: The SCT is reliable and useful to discriminate among participants according to their level of experience in radiation oncology. It appears as a useful tool to document the progression of reasoning during residency training.
ACCESSION #
42095021

 

Related Articles

  • Circulating Tumor Cell Testing. Xue, Chengsen; Hill, Carla G.; Mc Closkey, Thomas W. // Applied Clinical Trials;Mar2013, Vol. 22 Issue 3, p32 

    The article discusses the benefits and limitations on a circulating tumor cell (CTC) test that are required to fulfill an unmet need in oncology clinical trials and disease management practices. It informs about CellSearch System by Veridex LLC which is designed to enrich and enumerate CTCs in...

  • The Clinical Trials Program at the ESRF Biomedical Beamline ID17: Status and Remaining Steps. Requardt, H.; Bravin, A.; Prezado, Y.; Bräuer-Krisch, E.; Renier, M.; Brochard, Th.; Berkvens, P.; Estève, F.; Elleaume, H.; Adam, J.-F.; Blattmann, H.; Laissue, J. A.; Kaser-Hotz, B.; Nemoz, C.; Berruyer, G. // AIP Conference Proceedings;6/24/2010, Vol. 1234 Issue 1, p161 

    For several years the ID17 Biomedical beamline at the ESRF has developed synchrotron radiation therapy preclinical programmes to treat aggressive brain tumours. Two techniques have been developed at the ESRF: a) The Microbeam Radiation Therapy (MRT) using spatially fractionated “white...

  • Chimioradiothérapie concomitante pour le traitement des cancers bronchiques non à petites cellules, localisés au thorax, inopérables ou non résécables. Hennequin, C.; Mornex, F.; Trédaniel, J. // Oncologie;Sep2008, Vol. 10 Issue 9, p531 

    Concomitant chemoradiation is the standard strategy for unresectable locally advanced non-small cell lung cancer (NSCLC). Its modalities used currently include three-dimensional conformal techniques, allowing dose escalation and sequential and concurrent combination with new generation cytotoxic...

  • Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738. Checkley, Stephen; MacCallum, Linda; Yates, James; Jasper, Paul; Luo, Haobin; Tolsma, John; Bendtsen, Claus // Scientific Reports;8/28/2015, p13545 

    Understanding the therapeutic effect of drug dose and scheduling is critical to inform the design and implementation of clinical trials. The increasing complexity of both mono, and particularly combination therapies presents a substantial challenge in the clinical stages of drug development for...

  • Radiation quality, like art, consists in drawing the line somewhere. Kunos, Charles A.; Petersen, Ivy A. // Frontiers in Oncology;Jun2013, Vol. 3, p1 

    The architects of phase I radiochemotherapy development programs impose a semblance of structured radiation 'intensity' and adverse event predictability upon radiation-anticancer agent interactions whose natural complexity and improper mixing would otherwise lead to dire health consequences. It...

  • Tyranny of the p-Value: The Conflict between Statistical Significance and Common Sense. Barnett, Michael L.; Mathisen, Annette // Journal of Dental Research;Jan1997, Vol. 76 Issue 1, p534 

    The author discusses the use of statistical method in science research and clinical study reports. It is argued that scientists often use p-value as an excuse not to perform actual scientific research and critically assess decisions. The need to find balance between statistical analyses and...

  • CONTINUING EDUCATION TEST / The Hidden Costs of Cancer Care: An Overview With Implications and Referral Resources for Oncology Nurses, p. 279.  // Clinical Journal of Oncology Nursing;Jun2004, Vol. 8 Issue 3, pE24 

    A continuing education test based on articles published in the June 1, 2004 issue of the "Clinical Journal of Oncology Nursing" is presented.

  • RTOG, US Oncology collaborate for expansion of cancer trials.  // Medical Device Daily;10/21/2008, Vol. 12 Issue 223, p4 

    The article reports on the agreement between the Radiation Therapy Oncology Group (RTOG) and US Oncology in October 2008 which is aimed to increase patient access to national cancer clinical trials in a community setting. The scope of the accessibility to RTOG trials is highlighted. It...

  • EAB Reacts to Non-Traditional Article.  // Applied Clinical Trials;Mar2013, Vol. 22 Issue 3, p14 

    A review of the article "Patient-First Approach to Improve Oncology Clinical Trials," by Linda Strause which appeared in the periodical "Applied Clinical Trials," on March 1, 2013 is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics